Nuvectis Pharma

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

NVCT

Biotech

News

Health Care

Movers

Trading Ideas

General

Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing.

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Wall Street

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

ACIU

SOWG

UAVS

VISL

S&amp;P 500 Moves Lower; US Crude Oil Inventories Increase

Oil Price Photo by William Potter on Shutterstock

GXAI

Dow Falls Over 100 Points; US Producer Prices Rise In October

Nuvectis Pharma Inc

Press Releases

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort

Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Financing

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets

Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Alector

C4 Therapeutics

Editas Medicine

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genelux

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Seres Therapeutics

Macrogenics

Nanobiotix

Nkarta

ProKidney Corp. - Class A Ordinary Shares

ProKidney

RAPT Therapeutics

Renovaro

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Instil Bio

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

2seventy bio

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

HC Wainwright & Co.

Ladenburg Thalmann

Comments

Nuvectis Pharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga